AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
== Accords == On February 19, 2015, representatives from the Malian government and the Coordination of Azawad Movements (CMA) agreed upon a new document, including the cessation of hostilities, as negotiations to end the broader war continued in Algiers. On March 1, a mediation agreement was proposed by Algeria, which was accepted by Mali and pro-government militias. The CMA asked for some time to consider the agreement, as there were no propositions for autonomy or federalism for northern Mali, which angered a large portion of Tuareg rebels. The CMA announced their refusal to sign the agreement on April 10. On April 27, the pro-government GATIA and Arab Movement of Azawad (MAA) captured Menaka, initiating new clashes between Tuareg rebels and the pro-government militias. On May 10, the CMA initialized the agreement, but did not sign the text. The peace agreement was signed on May 15 in Bamako by the Malian government, representatives of pro-government militias, and representatives from Algeria, Burkina Faso, Mauritania, Niger, Nigeria, Chad, the African Union, the United Nations, ECOWAS, the Organisation of Islamic Cooperation, the European Union, and France. No CMA representatives were present for the signing on May 15. That same day, fighting broke out near Menaka. Under pressure from international organizations, the CMA finally signed the agreement in Bamako on June 20. The CMA's representative was Sidi Brahim Ould Sidati, a leader of the MAA.
For this reason, certain methods construct a background tree using 16S rRNA sequences which they use as the canonical tree of life. The distance matrix constructed from this tree of life is then subtracted from the distance matrices of the proteins of interest. However, because RNA distance matrices and DNA distance matrices have different scale, presumably because RNA and DNA have different mutation rates, the RNA matrix needs to be rescaled before it can be subtracted from the DNA matrices. By using molecular clock proteins, the scaling coefficient for protein distance/RNA distance can be calculated. This coefficient is used to rescale the RNA matrix.
The situation during Tehuantepecers and Santa Ana wind events are more complicated, as they occur when air rushing southward due to cold air damming east of the Sierra Madre Oriental and Sierra Nevada respectively, is accelerated when it moves through gaps in the terrain. The Santa Ana is further complicated by down-sloped air, or foehn winds, drying out and warming up in the lee of the Sierra Nevada and coastal ranges, leading to a dangerous wildfire situation.
Sources: en.wikipedia.org
Intradialytic parenteral nutrition (IDPN) is a nutritional support therapy (medical nutrition therapy) for people on hemodialysis who have a difficult time maintaining adequate nutrition. It is administered directly into the bloodstream of patients with chronic kidney disease (CKD) in an effort to decrease the associated morbidity and mortality experienced in patients with kidney failure. IDPN contains protein (amino acids), carbohydrates (dextrose), and fats (lipids) in an attempt to meet a patient's weekly nutritional needs. Solutions can be individualized for each patient based on weight, needs, medical history and enteral intake.
The calculations given above produce dates in radiocarbon years: i.e. dates that represent the age the sample would be if the 14C/12C ratio had been constant historically. Although Libby had pointed out as early as 1955 the possibility that this assumption was incorrect, it was not until discrepancies began to accumulate between measured ages and known historical dates for artefacts that it became clear that a correction would need to be applied to radiocarbon ages to obtain calendar dates. To produce a curve that can be used to relate calendar years to radiocarbon years, a sequence of securely dated samples is needed which can be tested to determine their radiocarbon age. The study of tree rings led to the first such sequence: individual pieces of wood show characteristic sequences of rings that vary in thickness because of environmental factors such as the amount of rainfall in a given year. These factors affect all trees in an area, so examining tree-ring sequences from old wood allows the identification of overlapping sequences. In this way, an uninterrupted sequence of tree rings can be extended far into the past. The first such published sequence, based on bristlecone pine tree rings, was created by Wesley Ferguson. Hans Suess used this data to publish the first calibration curve for radiocarbon dating in 1967. The curve showed two types of variation from the straight line: a long term fluctuation with a period of about 9,000 years, and a shorter-term variation, often referred to as "wiggles", with a period of decades.
In early 1936, Thomas met Caitlin Macnamara (1913–1994), a 22-year-old dancer of Irish and French Quaker descent. She had run away from home, intent on making a career in dance, and aged 18 joined the chorus line at the London Palladium. Introduced by Augustus John, Caitlin's lover, they met in The Wheatsheaf pub on Rathbone Place in London's West End. Laying his head in her lap, a drunken Thomas proposed. Thomas liked to assert that he and Caitlin were in bed together ten minutes after they first met. Although Caitlin initially continued her relationship with John, she and Thomas began a correspondence, and in the second half of 1936 were courting. They married at the register office in Penzance, Cornwall, on 11 July 1937. For the first months of their relationship and marriage the couple lived at the Macnamara family home in Blashford, Hampshire. In May 1938 they moved to Wales, to the village of Laugharne, Carmarthenshire where they rented a cottage in Gosport Street before moving into 'Sea View', a larger property, a couple of months later. They left Laugharne in July 1940 and then led a peripatetic lifestyle over the next few years, returning to Blashford and subsequently living at Marshfield (1940), Bishopston (1940–41), Chelsea, in London (1942–43), Talsarn (1942–44), East Knoyle, Beaconsfield (1944), Bosham, Sussex (1944), Blaencwm (Llansteffan) (1944 and 1945), New Quay (1944–45), and in premises arranged by Margaret Taylor, one of Dylan's benefactors (the wife of the historian A. J. P.
Hahn's intention was still to work in industry. He received an offer of employment from Eugen Fischer, the director of Kalle & Co. (and the father of organic chemist Hans Fischer), but a condition of employment was that Hahn had to have lived in another country and have a reasonable command of another language. With this in mind, and to improve his knowledge of English, Hahn took up a post at University College London in 1904, working under Sir William Ramsay, who was known for having discovered the noble gases. Here Hahn worked on radiochemistry, at that time a very new field. In early 1905, in the course of his work with salts of radium, Hahn discovered a new substance he called radiothorium (thorium-228), which at that time was believed to be a new radioactive element. In fact, it was an isotope of the known element thorium; the concept of an isotope, along with the term, was coined in 1913 by the British chemist Frederick Soddy. Ramsay was enthusiastic when yet another new element was found in his institute, and he intended to announce the discovery in a correspondingly suitable way. In accordance with tradition this was done before the committee of the venerable Royal Society. At the session of the Royal Society on 16 March 1905 Ramsay communicated Hahn's discovery of radiothorium. The Daily Telegraph informed its readers:
Sources: en.wikipedia.org
=== Active regions === A model based on electron crystallographic density and nuclear magnetic resonance deconvolution has been proposed to explain the binding of docetaxel to β-tubulin. In this T-shaped/butterfly model, a deep hydrophobic cleft exists near the surface of the β-tubulin where three potential hydrogen bonds and multiple hydrophobic contacts bind to docetaxel. The hydrophobic pocket walls contain helices H1, H6, H7 and a loop between H6 and H7 that form hydrophobic interactions with the 3'-benzamido phenyl, 3'-phenyl, and the 2-benzoyl phenyl of docetaxel. 3'-phenyl also has contact with β-sheets B8 and B10. The C-8 methyl of docetaxel has Van der Waals interactions with two residues, Thr-276 and Gln-281 near the C-terminal end of β-tubulin. Docetaxel's O-21 experiences electrostatic attraction to Thr-276 and the C-12 methyl has proximity with Leu-371 on the loop between B9 and B10.
President Bill Clinton's administration Greg Burke (1982), former Fox News correspondent and director the Holy See Press Office Claire Shipman (1986), ABC News correspondent Elizabeth Cohen (1987), CNN's senior medical correspondent Alexandra Wallace (1988), executive producer of NBC Nightly News Soterios Johnson (1990), host of Morning Edition on National Public Radio Alexis Glick (1994), anchorwoman for the Fox Business Network Suzy Shuster (1994), Emmy Award-winning sportscaster with ABC Sports Max Kellerman (1998), boxing commentator and host of HBO World Championship Boxing Gideon Yago (2000), MTV News correspondent Jonathan Lemire (2001), journalist and host of MSNBC's Way Too Early Charlotte MacInnis (2002), China Central Television anchor known by the stage name Ai Hua; host of Growing up with Chinese Buzzy Cohen (2007), Jeopardy! guest host and contestant, co-host of The Chase Meghan McCain (2007), former co-host of The View, blogger and daughter of Arizona senator John McCain
== Preservation == Following transport and burial, diagenetic processes saturate the hydrocarbon chain, turning it into the fully saturated structure of chlorobactane. Isoreneiratene is an aromatic light-harvesting molecule interpreted as a biomarker for brown-pigmented GSB in the same order, Chlorobiales, and its fossil form (isorenieratane) is often found co-occurring with chlorobactene in ancient organic material. Purple sulfur bacteria (PSB) also live in euxinic regions. They produce a different accessory pigment, okenone, that is preserved as okenane and often observed co-occurring with chlorobactane.
==== United States ==== 2003: Meloxicam was approved in the US for use in dogs for the management of pain and inflammation associated with osteoarthritis, as an oral (liquid) formulation of meloxicam. 2003 (November): An injectable formulation for use in dogs was approved by the US Food and Drug Administration (FDA). 2004 (October): A formulation for use in cats was approved for use before surgery only. This is an injectable meloxicam, indicated for as a single, one-time dose only, with specific and repeated warnings not to administer a second dose. 2005 (January): The product insert added a warning in bold-face type: "Do not use in cats." 2005: The FDA sent a Notice of Violation to the manufacturer for its promotional materials which included promotion of the drug for off-label use. 2020 (February): A meloxicam injection was approved for use in the United States. Specifically, the FDA granted the approval of Anjeso to Baudax Bio.
== Pharmacology == Dimethyl fumarate is metabolized to monomethyl fumarate (MMF) prior to entering systemic distribution. Dimethyl fumarate has been described a prodrug. Dimethyl fumarate is a precursor of monomethyl fumarate. Other prodrugs that metabolize to monomethyl fumarate have been developed to treat relapse-remitting multiple sclerosis, including diroximel fumarate which was approved by the FDA in October 2019. The precise mechanism of action of dimethyl fumarate is not clear. Dimethyl fumarate and monomethyl fumarate can activate the transcription factor (Nuclear factor erythroid-derived 2)-related factor 2 (Nrf2) pathway and monomethyl fumarate has been identified as a nicotinic acid receptor agonist in vitro. In mice that lack Nrf2 expression, however, dimethyl fumarate is still able to modulate the immune system, which indicates that Nrf2 is not required for its immunomodulatory action. For psoriasis, the mechanism of action is believed to be due to the interaction of monomethyl fumarate and the intracellular reduced glutathione of cells directly involved in the pathogenesis of psoriasis. The interaction with glutathione leads to the inhibition of nuclear translocation and the transcriptional activity of the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Dimethyl fumarate and monomethyl fumarate have been shown to reduce the expression of micro-RNA-21, which is essential for the production of pathogenic cells in multiple sclerosis and psoriasis.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.